| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Lactoferrin (17-41) acetate targets multiple cellular processes including microbial membranes and cancer cell signaling pathways. The peptide exerts antimicrobial effects by disrupting microbial membranes, leading to cell death. Its antiviral activity is mediated through interactions with viral envelopes or host cell receptors. The peptide's antitumor activities are mediated through induction of apoptosis, as demonstrated by its cytotoxic action on HT-29 cells. Lactoferrin (17-41) acetate regulates the transcription of genes such as PMAIP-1, TP5313, and SFN that are involved in the p53 signaling pathway. This modulation of p53 pathway genes contributes to its pro-apoptotic effects in cancer cells. The peptide's broad-spectrum activity makes it effective against various pathogens.
|
|---|---|
| ln Vitro |
The minimum inhibitory concentration (MIC) of lactoferrin 17-41 (lacoferrin B) acetate against Escherichia coli ATCC 25922 is 30 μg/mL [1]. Lactoferrin 17–41 acetate exhibits cytotoxic action on HT-29 cells and dramatically increases HT-29 cell apoptosis [2]. To varied degrees, lactoferrin 17–41 acetate can control the transcription of genes such PMAIP-1, TP5313, and SFN that are implicated in the p53 signaling pathway[2]. Human monocyte LPS-induced cytokine responses can be inhibited by lactoferrin 17-41 acetate, which can bind LPS from Gram-negative bacteria [1][3].
In vitro, lactoferrin (17-41) acetate has demonstrated potent antimicrobial and antitumor activities. It exhibits antimicrobial activity against a wide range of microorganisms including Gram-positive and Gram-negative bacteria, viruses, protozoa, and fungi. The peptide shows cytotoxic action on HT-29 cells and dramatically increases HT-29 cell apoptosis. It regulates the transcription of genes involved in the p53 signaling pathway, including PMAIP-1, TP5313, and SFN, to varying degrees. Its antitumor activities have been demonstrated in various cancer cell lines. The peptide's antimicrobial and antitumor effects are dose-dependent. These in vitro activities make it a valuable reagent for infection control and cancer research. |
| ln Vivo |
In vivo, lactoferrin (17-41) acetate has been studied for its antimicrobial and antitumor activities. The peptide's broad-spectrum antimicrobial properties suggest potential applications in treating infections. Its antitumor activities, including induction of apoptosis in cancer cells, indicate potential for cancer therapy. However, detailed in vivo efficacy and safety data are limited. As a peptide derived from the antimicrobial domain of lactoferrin, it may have favorable safety properties. Further research is needed to fully characterize its in vivo biological activity, therapeutic potential, and safety profile. The peptide is intended for research use only and not for human therapeutic applications without appropriate evaluation.
|
| Enzyme Assay |
For in vitro biochemical assays, lactoferrin (17-41) acetate is evaluated for its antimicrobial and antitumor activities. Antimicrobial activity is assessed using broth microdilution or agar diffusion methods to determine minimum inhibitory concentrations (MIC) against various bacteria, fungi, and protozoa. Antiviral activity is evaluated using plaque reduction assays or viral titer reduction assays. Antitumor activity is assessed by measuring cell viability, proliferation, and apoptosis in cancer cell lines. Gene expression analysis is performed using qPCR to assess regulation of p53 pathway genes. Protein concentration and purity are assessed using standard methods. These cell-free and cell-based assays help characterize the peptide's biological activities and mechanisms of action.
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: HT-29 cells Tested Concentrations: 50, 100, 200, 400, 800 or 1000 µg/mL Incubation Duration: 4, 12, 24 or 48 hrs (hours) Experimental Results: More effective at inducing apoptosis at 400 µg/mL. Higher toxicity is shown at 800 µg/mL. In vitro cellular assays for lactoferrin (17-41) acetate are performed using various cell types including HT-29 colon cancer cells. Cells are cultured in standard media and treated with the peptide at various concentrations for 24-72 hours. Cell viability is assessed using MTT or CCK-8 assays. Apoptosis is evaluated by measuring caspase 3/7 activity, Annexin V/PI staining, and DNA fragmentation. Gene expression of p53 pathway targets including PMAIP-1, TP5313, and SFN is analyzed by qPCR. Antimicrobial activity is tested against bacterial and fungal cultures by measuring growth inhibition. Antiviral activity is assessed using virus-infected cell cultures. These cellular assays help validate the peptide's antimicrobial and antitumor activities and characterize its mechanism of action. |
| Animal Protocol |
In vivo animal experiments with lactoferrin (17-41) acetate are limited, as the peptide is primarily used as a research tool. If used in animal studies, typical approaches would involve administration via intraperitoneal injection, intravenous injection, or oral gavage. Infection models using bacterial, viral, or fungal pathogens could be used to assess antimicrobial efficacy. Tumor xenograft models could be employed to evaluate antitumor activity. Dosing regimens would be determined from pharmacokinetic and tolerability studies. Efficacy endpoints would include pathogen load reduction, tumor growth inhibition, and survival. Tissue samples would be analyzed for gene expression and histological changes. Researchers should consult the primary literature for any available in vivo data.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of lactoferrin (17-41) acetate are not extensively documented. As a peptide derived from bovine lactoferrin, it is expected to have limited oral bioavailability due to proteolytic degradation in the gastrointestinal tract. The peptide would likely require parenteral administration for systemic effects. Its stability in biological fluids would depend on resistance to proteases. The peptide's small size (25 amino acids) compared to full-length lactoferrin may affect its distribution and clearance. Detailed PK parameters such as half-life, Cmax, Tmax, AUC, volume of distribution, and clearance are not available in the literature. Researchers should consult the primary literature for any available pharmacokinetic data.
|
| Toxicity/Toxicokinetics |
The toxicological profile of lactoferrin (17-41) acetate is not extensively characterized. As a peptide corresponding to the antimicrobial domain of bovine lactoferrin, it is expected to have a favorable safety profile similar to the parent protein. However, comprehensive toxicity studies including acute, subchronic, and chronic toxicity assessments are limited. The peptide's antimicrobial activity against a broad range of microorganisms suggests potential for selective toxicity against pathogens. Its antitumor activities indicate potential for therapeutic applications but also raise considerations for safety. The peptide is intended for research use only and not for human therapeutic applications without appropriate safety evaluation. Researchers should follow standard laboratory safety practices when handling this peptide.
|
| References |
|
| Additional Infomation |
Lactoferrin (17-41) acetate is a valuable research tool for studying antimicrobial and antitumor activities of lactoferrin-derived peptides. Its broad-spectrum antimicrobial properties make it useful for investigating mechanisms of antimicrobial action and developing new antimicrobial agents. The peptide's antitumor activities, including induction of apoptosis in cancer cells, provide opportunities for studying cancer cell death mechanisms and developing anticancer therapies. Its regulation of p53 pathway genes makes it relevant for studying p53 signaling and apoptosis. The peptide can be employed to study structure-activity relationships in antimicrobial and anticancer peptides, and to develop peptide-based therapeutics for infection control and cancer treatment.
|
| Molecular Formula |
C143H228N46O31S3
|
|---|---|
| Molecular Weight |
3183.83
|
| Exact Mass |
3182.687
|
| CAS # |
2828433-30-1
|
| Related CAS # |
Lactoferrin (17-41);146897-68-9
|
| PubChem CID |
166450479
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
49
|
| Hydrogen Bond Acceptor Count |
43
|
| Rotatable Bond Count |
73
|
| Heavy Atom Count |
223
|
| Complexity |
6980
|
| Defined Atom Stereocenter Count |
26
|
| SMILES |
C(=O)(O)C.C([C@@H]1NC(=O)C(NC([C@@]([H])(NC([C@H](CSSC[C@]([H])(NC([C@@]([H])(NC([C@@]([H])(NC([C@@H](NC([C@]2([H])CCCN2C(=O)[C@H](C)NC(=O)CNC(=O)[C@]([H])(CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@]([H])(CCCCN)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCNC(N)=N)NC(=O)C(CC2=CNC3=CC=CC=C23)NC(=O)[C@H](CCC(=O)N)NC1=O)=O)CO)=O)[C@@H](C)CC)=O)[C@H](O)C)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)O)CC1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1C=CC=CC=1)=O)CCCNC(N)=N)=O)CCCNC(N)=N)C1=CNC2=CC=CC=C12
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 20 mg/mL (6.28 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2 mg/mL (0.63 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2 mg/mL (0.63 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2 mg/mL (0.63 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.3141 mL | 1.5704 mL | 3.1409 mL | |
| 5 mM | 0.0628 mL | 0.3141 mL | 0.6282 mL | |
| 10 mM | 0.0314 mL | 0.1570 mL | 0.3141 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
